There's good news for people who suffer with severe treatment-resistant depression. Esketamine is a groundbreaking therapy that may provide relief from major depression within hours. Join this livestream to hear psychiatrist Erica Richards, chair and medical director of the Department of Psychiatry and Behavioral Health at Sibley Memorial Hospital, describe who is a candidate for esketamine, which is derived from an anesthetic called ketamine, and how it works, and psychopharmacologist Roland Griffiths, Professor in the Departments of Psychiatry and Neurosciences at the Johns Hopkins University School of Medicine, will tell us about psilocybin research and risk factors of the drug. To learn more, visit jhu.edu/hopkinsathome